This company has been acquired
SILK Stock Overview
Operates as a medical device company in the United States. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 1/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Community vs My Fair Value
Create NarrativeSelect a narrative for quick price alerts from the community, or create your own.
Silk Road Medical, Inc Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$27.49 |
| 52 Week High | US$27.51 |
| 52 Week Low | US$6.08 |
| Beta | 1.54 |
| 1 Month Change | 1.36% |
| 3 Month Change | 2.27% |
| 1 Year Change | 66.40% |
| 3 Year Change | -50.71% |
| 5 Year Change | -19.74% |
| Change since IPO | -24.02% |
Recent News & Updates
Recent updates
Silk Road Medical, Inc (NASDAQ:SILK) First-Quarter Results Just Came Out: Here's What Analysts Are Forecasting For This Year
May 03
Is Silk Road Medical (NASDAQ:SILK) A Risky Investment?
May 02Silk Road Medical, Inc's (NASDAQ:SILK) Shares Leap 35% Yet They're Still Not Telling The Full Story
Feb 03A Piece Of The Puzzle Missing From Silk Road Medical, Inc's (NASDAQ:SILK) 26% Share Price Climb
Dec 20Is Silk Road Medical (NASDAQ:SILK) Weighed On By Its Debt Load?
Nov 03Is Silk Road Medical (NASDAQ:SILK) A Risky Investment?
Aug 05Shareholders Should Be Pleased With Silk Road Medical, Inc's (NASDAQ:SILK) Price
May 05Is Silk Road Medical (NASDAQ:SILK) A Risky Investment?
Apr 04Silk Road Medical announces $100M common stock offering
Oct 17Is Silk Road Medical (NASDAQ:SILK) Using Too Much Debt?
Sep 24Silk Road Medical GAAP EPS of -$0.44 beats by $0.02, revenue of $33.17M beats by $2.14M
Jul 26Silk Road Medical: Divergence From Alternative Risk Premia Means Lack Of Upside Capture
Jul 19Shareholder Returns
| SILK | US Medical Equipment | US Market | |
|---|---|---|---|
| 7D | 1.5% | -0.6% | -3.4% |
| 1Y | 66.4% | 3.9% | 6.1% |
Return vs Industry: SILK exceeded the US Medical Equipment industry which returned 17.2% over the past year.
Return vs Market: SILK exceeded the US Market which returned 24.4% over the past year.
Price Volatility
| SILK volatility | |
|---|---|
| SILK Average Weekly Movement | 6.8% |
| Medical Equipment Industry Average Movement | 8.6% |
| Market Average Movement | 6.4% |
| 10% most volatile stocks in US Market | 16.8% |
| 10% least volatile stocks in US Market | 3.3% |
Stable Share Price: SILK has not had significant price volatility in the past 3 months.
Volatility Over Time: SILK's weekly volatility (7%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2007 | 474 | Chas McKhann | silkroadmed.com |
Silk Road Medical, Inc operates as a medical device company in the United States. The company offers various products for the treatment of carotid artery disease called transcarotid artery revascularization (TCAR). Its products comprise ENROUTE Transcarotid Neuroprotection System that is used to directly access the common carotid artery and establish temporary blood flow reversal; ENROUTE Transcarotid Stent System for transcarotid access; ENHANCE Transcarotid Peripheral Access Kit, which is used to gain initial access to the common carotid artery; ENROUTE 0.014 Guidewire for atraumatic vessel navigation and target lesion crossing for delivery of interventional devices; and ENROUTE Enflate Transcarotid RX Balloon Dilation Catheter, a transcarotid rapid exchange balloon for the TCAR procedure.
Silk Road Medical, Inc Fundamentals Summary
| SILK fundamental statistics | |
|---|---|
| Market cap | US$1.12b |
| Earnings (TTM) | -US$56.54m |
| Revenue (TTM) | US$191.43m |
5.8x
P/S Ratio-19.8x
P/E RatioIs SILK overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| SILK income statement (TTM) | |
|---|---|
| Revenue | US$191.43m |
| Cost of Revenue | US$49.24m |
| Gross Profit | US$142.19m |
| Other Expenses | US$198.73m |
| Earnings | -US$56.54m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.39 |
| Gross Margin | 74.28% |
| Net Profit Margin | -29.53% |
| Debt/Equity Ratio | 49.2% |
How did SILK perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/09/16 20:19 |
| End of Day Share Price | 2024/09/16 00:00 |
| Earnings | 2024/06/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Silk Road Medical, Inc is covered by 9 analysts. 8 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| null null | Argus Research Company |
| Joanne Wuensch | BMO Capital Markets Equity Research |
| Travis Steed | BofA Global Research |